Therapeutic agent for pulmonary fibrosis

Abstract

Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for pulmonary fibrosis, which utilized the carrier; and a preparation kit of the therapeutic agent.

1 . A substance delivery carrier to an extracellular matrix-producing cell in the lung, comprising a retinoid as a targeting agent. 
     
     
         2 . The carrier according to  claim 1 , wherein the retinoid derivative comprises retinol. 
     
     
         3 . The carrier according to  claim 1 , wherein the retinoid content is 0.2-20 wt % of the entire carrier. 
     
     
         4 . The carrier according to  claim 2 , wherein the retinoid content is 0.2-20 wt % of the entire carrier. 
     
     
         5 . The carrier according to  claim 1 , wherein the carrier has a form of liposome, and the molar ratio of the retinoid to the lipid contained in the liposome is 8:1-1:4. 
     
     
         6 . The carrier according to  claim 2 , wherein the carrier has a form of liposome, and the molar ratio of the retinoid to the lipid contained in the liposome is 8:1-1:4. 
     
     
         7 . The carrier according to  claim 3 , wherein the carrier has a form of liposome, and the molar ratio of the retinoid to the lipid contained in the liposome is 8:1-1:4. 
     
     
         8 . The carrier according to  claim 4 , wherein the carrier has a form of liposome, and the molar ratio of the retinoid to the lipid contained in the liposome is 8:1-1:4. 
     
     
         9 . A composition for treating pulmonary fibrosis, comprising the carrier according to  claim 1  and a drug that controls the activity or growth of extracellular matrix-producing cells in the lung. 
     
     
         10 . The composition according to  claim 9 , wherein the drug that controls the activity or growth of extracellular matrix-producing cells in the lung is selected from the group consisting of an agent for inhibiting activity or production of a bioactive substance selected from the group consisting of gelatinase A, gelatinase B and angiotensinogen, an inhibitor of cell activity, a growth inhibitor, an apoptosis-inducing agent, as well as an siRNA, a ribozyme, an anti-sense nucleic acid, and a DNA/RNA chimeric polynucleotide which target at least one of extracellular matrix constituent molecules or molecules involved in the production or secretion of said extracellular matrix constituent molecules, and a vector that expresses said siRNA, ribozyme, anti-sense nucleic acid, and DNA/RNA chimeric polynucleotide. 
     
     
         11 . The composition according to  claim 10 , wherein the molecule involved in the production or secretion of the extracellular matrix constituent molecules is HSP47. 
     
     
         12 . The composition according to  claim 9 , wherein the drug and the carrier are mixed at a place of medical treatment or in its vicinity. 
     
     
         13 . A kit for preparing the composition according to  claim 9 , wherein the kit comprises one or more containers comprising singly or in combination a drug for inhibiting activity or growth of extracellular matrix-producing cells in the lung, a retinoid, and if necessary, a carrier-constituent substance other than retinoid. 
     
     
         14 . A composition for treating pulmonary fibrosis, comprising the carrier according to  claim 2  and a drug that controls the activity or growth of extracellular matrix-producing cells in the lung. 
     
     
         15 . The composition according to  claim 14 , wherein the drug that controls the activity or growth of extracellular matrix-producing cells in the lung is selected from the group consisting of an agent for inhibiting activity or production of a bioactive substance selected from the group consisting of gelatinase A, gelatinase B and angiotensinogen, an inhibitor of cell activity, a growth inhibitor, an apoptosis-inducing agent, as well as an siRNA, a ribozyme, an anti-sense nucleic acid, and a DNA/RNA chimeric polynucleotide which target at least one of extracellular matrix constituent molecules or molecules involved in the production or secretion of said extracellular matrix constituent molecules, and a vector that expresses said siRNA, ribozyme, anti-sense nucleic acid, and DNA/RNA chimeric polynucleotide. 
     
     
         16 . The composition according to  claim 15 , wherein the molecule involved in the production or secretion of the extracellular matrix constituent molecules is HSP47. 
     
     
         17 . The composition according to  claim 14 , wherein the drug and the carrier are mixed at a place of medical treatment or in its vicinity. 
     
     
         18 . A kit for preparing the composition according to  claim 14 , wherein the kit comprises one or more containers comprising singly or in combination a drug for inhibiting activity or growth of extracellular matrix-producing cells in the lung, a retinoid, and if necessary, a carrier-constituent substance other than retinoid. 
     
     
         19 . A composition for treating pulmonary fibrosis, comprising the carrier according to  claim 5  and a drug that controls the activity or growth of extracellular matrix-producing cells in the lung. 
     
     
         20 . The composition according to  claim 19 , wherein the drug that controls the activity or growth of extracellular matrix-producing cells in the lung is selected from the group consisting of an agent for inhibiting activity or production of a bioactive substance selected from the group consisting of gelatinase A, gelatinase B and angiotensinogen, an inhibitor of cell activity, a growth inhibitor, an apoptosis-inducing agent, as well as an siRNA, a ribozyme, an anti-sense nucleic acid, and a DNA/RNA chimeric polynucleotide which target at least one of extracellular matrix constituent molecules or molecules involved in the production or secretion of said extracellular matrix constituent molecules, and a vector that expresses said siRNA, ribozyme, anti-sense nucleic acid, and DNA/RNA chimeric polynucleotide. 
     
     
         21 . The composition according to  claim 20 , wherein the molecule involved in the production or secretion of the extracellular matrix constituent molecules is HSP47. 
     
     
         22 . The composition according to  claim 19 , wherein the drug and the carrier are mixed at a place of medical treatment or in its vicinity. 
     
     
         23 . A kit for preparing the composition according to  claim 19 , wherein the kit comprises one or more containers comprising singly or in combination a drug for inhibiting activity or growth of extracellular matrix-producing cells in the lung, a retinoid, and if necessary, a carrier-constituent substance other than retinoid.